Politics of Intellectual Property
Show Less

Politics of Intellectual Property

Contestation Over the Ownership, Use, and Control of Knowledge and Information

Edited by Sebastian Haunss and Kenneth C. Shadlen

This book offers empirical analyses of conflicts over the ownership, control, and use of knowledge and information in developed and developing countries.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 3: The Politics of Patents: Conditions of Implementation of Public Health Policy in Thailand

Gaëlle Krikorian


Gaëlle Krikorian INTRODUCTION At the end of 2006, the Thai Minister of Public Health, Mongkol Na Songkhla, made the decision to override patent protection by implementing article 51 of the Thai Patent Act on an HIV/AIDS medication, in order to generate – through import and local production – the necessary generic supplies. In doing so, he made use of a provision called compulsory licensing. Soon thereafter, Thailand came under attack; hailing from the American administration, the US Congress, and multinational companies, the critics were virulent. For Harvey Bale, director of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), “Compulsory licensing can be a route to commercial abuse and can put patients at risk” (Kazmin and Jack, 2007). In recent years, most of the developing country members of the World Trade Organization (WTO) have implemented the standards of “intellectual property” (IP) protection1 required by the organization. One of the consequences is 20-year patent protection on medicine, which forbids production, importation, or marketing of generics for this duration. Studies have highlighted the negative impact of this increased IP protection on access to health products in these countries (Subramanian, 1995; Remiche and Desterbecq, 1996; Velásquez and Boulet, 1999; Correa, 2000). In response to these concerns, and in particular in reaction to the international mobilization for access to anti-HIV medicines, the issue of how IP in pharmaceuticals affects access to medicines and public health became the subject of intense debate at the WTO. This debate led to the 2001 adoption of the Doha...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.